These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 23356833)

  • 1. Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A.
    Lee JH; Park JH; Lee SK; Han KH; Kim SD; Yoon CS; Park JY; Lee JH; Yang JM; Lee JH
    J Dermatolog Treat; 2014 Aug; 25(4):326-30. PubMed ID: 23356833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients.
    Lee SH; Wee SH; Kim HJ; Yeo UC; Lee NH; Lee SW; Cho SB
    J Dermatolog Treat; 2013 Apr; 24(2):133-6. PubMed ID: 21888570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides.
    Matarasso SL
    Dermatol Surg; 2003 Jan; 29(1):7-13; discussion 13. PubMed ID: 12534505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement.
    Kim HJ; Yum KW; Lee SS; Heo MS; Seo K
    Dermatol Surg; 2003 May; 29(5):484-9. PubMed ID: 12752515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-center, open-label, randomized, split-face study to assess the efficacy and safety of one versus three intradermal injection sites of abobotulinumtoxinA in the treatment of lateral periocular rhytides.
    Fabi SG; Sundaram H; Guiha I; Goldman MP
    J Drugs Dermatol; 2013 Aug; 12(8):932-7. PubMed ID: 23986168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of administering abobotulinumtoxinA through a single injection point when treating lateral periocular rhytides.
    Kiripolsky MG; Goldman MP
    J Cosmet Dermatol; 2011 Sep; 10(3):232-4. PubMed ID: 21896136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The change of maximum bite force after botulinum toxin type a injection for treating masseteric hypertrophy.
    Ahn KY; Kim ST
    Plast Reconstr Surg; 2007 Nov; 120(6):1662-1666. PubMed ID: 18040203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.
    Carraro E; Trevisi E; Martinuzzi A
    Eur J Paediatr Neurol; 2016 Jul; 20(4):532-7. PubMed ID: 27177451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of botulinum toxin type A on contouring of the lower face.
    Choe SW; Cho WI; Lee CK; Seo SJ
    Dermatol Surg; 2005 May; 31(5):502-7; discussion 507-8. PubMed ID: 15962731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides.
    Carruthers A; Carruthers J; Cohen J
    Dermatol Surg; 2003 May; 29(5):461-7. PubMed ID: 12752512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of botulinum toxin type A for the treatment of masseteric muscle hypertrophy.
    Arikan OK; Tan FU; Kendi T; Koc C
    J Otolaryngol; 2006 Feb; 35(1):40-3. PubMed ID: 16527016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation and selecting indications for the treatment of improving facial morphology by masseteric injection of botulinum toxin type A.
    Gaofeng L; Jun T; Bo P; Bosheng Z; Qian Z; Dongping L
    J Plast Reconstr Aesthet Surg; 2010 Dec; 63(12):2026-31. PubMed ID: 20116356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type A treatment for contouring of the lower face.
    Park MY; Ahn KY; Jung DS
    Dermatol Surg; 2003 May; 29(5):477-83; discussion 483. PubMed ID: 12752514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis.
    Yamauchi PS; Lowe NJ
    Clin Dermatol; 2004; 22(1):34-9. PubMed ID: 15158543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The topographic anatomy of the masseteric nerve: A cadaveric study with an emphasis on the effective zone of botulinum toxin A injections in masseter.
    Kaya B; Apaydin N; Loukas M; Tubbs RS
    J Plast Reconstr Aesthet Surg; 2014 Dec; 67(12):1663-8. PubMed ID: 25175271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of botulinum toxin type A in cosmetic facial procedures.
    Jaspers GW; Pijpe J; Jansma J
    Int J Oral Maxillofac Surg; 2011 Feb; 40(2):127-33. PubMed ID: 20965695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum Toxin Injections for Masseter Reduction in East Asians.
    Cheng J; Hsu SH; McGee JS
    Dermatol Surg; 2019 Apr; 45(4):566-572. PubMed ID: 30883483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multicenter Phase II Study Evaluating the Safety and Efficacy of Botulax in Asian Patients with Benign Masseteric Hypertrophy.
    Lee JS; Son HS; Kim BJ; Lee YW
    Plast Reconstr Surg; 2024 May; 153(5):910e-918e. PubMed ID: 37335589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemodenervation with botulinumtoxin in masseteric hypertrophy].
    Mischkowski RA; Siessegger M; Lazar F; Zöller JE
    Mund Kiefer Gesichtschir; 2005 Mar; 9(2):101-8. PubMed ID: 15711991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin A treatment of perioral rhytides.
    Semchyshyn N; Sengelmann RD
    Dermatol Surg; 2003 May; 29(5):490-5; discussion 495. PubMed ID: 12752516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.